The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis

Olumide Olutubosun Rowaiye, Mariusz Kusztal and Marian Klinger

Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland

Correspondence to: Mariusz Kusztal; E-mail: mariusz.kusztal@umed.wroc.pl

Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of pauci-immune small vessel vasculitides that often affect the kidneys manifesting as rapidly progressive glomerulonephritis. Although the exact pathogenesis of AAV is not fully known, evidence from in vitro, in vivo and clinical studies all point to the involvement of ANCA in the pathogenesis of AAV. In this review, we highlight the contributory roles played by various factors (e.g. genetics, environment, B and T-regulatory cells, toll-like receptors, etc.) in the pathogenesis of AAV. Furthermore, we discuss renal involvement in AAV in terms of clinical features and the various histopathological classification patterns, which are also known to be of prognostic importance. We also present information on useful imaging techniques for localizing kidney and other organ system involvement in AAV, and also on novel laboratory methods and assays useful for rapid and more specific determination of patients' ANCA status. Finally, we demonstrate evidence on novel serum biomarkers that have been shown to correlate with disease activity in AAV.

Keywords: antineutrophil cytoplasmic antibody-associated vasculitis; immunoassays; pathogenesis; renal histopathology; serum biomarkers

Introduction
The kidneys are highly vascularized visceral organs and are therefore commonly affected by various vasculitic syndromes [1, 2]. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of small vessel vasculitides that are described as pauci-immune (i.e. they are associated with few or no immune deposits) [1, 3]. They are characterized by the presence of ANCA in the circulation. It must be stated here that some AAV patients are ANCA-negative (i.e. they have no circulating ANCA) but still have similar disease manifestations as those who are ANCA-positive [4]. AAV can affect different blood vessels in the body leading to the damage of critical organs such as the heart, lungs, kidneys, nervous system, gastrointestinal system, skin, etc.; but for the purpose of this article, we shall focus on AAV as it affects the kidneys.

According to the International Chapel Hill Consensus Conference (CHCC) on the Nomenclature of vasculitides [5], AAV can be categorized into the following types:

(i) Microscopic polyangitis (MPA): a pauci-immune non-granulomatous necrotizing small vessel vasculitis that is frequently accompanied by necrotizing glomerulonephritis, pulmonary capillaritis and sometimes by the presence of necrotizing arteritis of small- and medium-sized arteries.

(ii) Granulomatosis with polyangitis (GPA, formerly called Wegener’s granulomatosis): a small vessel vasculitis characterized by the presence of necrotizing granulomatous inflammation of the respiratory tract, necrotizing vasculitis of small- to medium-sized vessels and by the frequent occurrence of necrotizing glomerulonephritis.

(iii) Eosinophilic granulomatosis with polyangitis (EGPA, formerly Churg–Strauss syndrome): a small vessel vasculitis characterized by the presence of granulomatous and eosinophil-rich inflammation of the respiratory tract, necrotizing vasculitis of small- to medium-sized vessels and an association with asthma and blood eosinophilia.

(iv) A fourth type of AAV called ‘renal limited vasculitis’ (RLV) or ‘idiopathic rapidly progressive glomerulonephritis’ (RPGN) also occurs and is characterized by the occurrence of pauci-immune crescentic glomerulonephritis in the absence of other systemic involvements [1].
At present, there are no validated diagnostic criteria for AAV [6] and the definitions of the different vasculitic syndromes presented above are not intended for disease classification or diagnosis but rather to provide a working description of the different syndromes that make up the AAV clinical spectrum. A clinical guide for the diagnosis of renal AAV is presented in Table 1.

AAV occur more frequently in Caucasians than in people of African descent, with the incidence being slightly greater in males than in females [1, 7]. Although AAV may occur at any age, the typical age of disease onset is between the fifth and the seventh decades of life [1, 7]. The estimated disease incidence is 15–23 per million population [8]. The specific vasculitic syndromes comprising AAV also appear to show geographical variation. For instance, in Northern Europe, GPA occurs more commonly than MPA while EGPA is the least predominant in this region [9]. However, in Southern Europe and Japan, MPA occurs more frequently than GPA [9]. Results from epidemiological studies in one region of Northern Germany showed a doubled rate of prevalence of AAV in this region over a period of ~12 years [10].

### ANCA and other antibodies associated with AAV

ANCA are autoantibodies targeted against antigens present in the cytoplasm of neutrophils and monocytes. The most common target antigens for ANCA are protei

| Table 1. Clinical guide for the diagnosis of renal AAV |
|----------------------------------------------------|
| 1. Clinical features of renal involvement (e.g. haematuria, proteinuria, active urinary sediment, renal failure) |
| 2. Serological assessment (ANCA testing) |
| 3. Histopathological evidence (positive renal biopsy) |

"This does not represent a diagnostic criteria for renal AAV but rather serves as a guide; at present, there are no validated diagnostic criteria for AAV.

| Table 2. Differential diagnosis of AAV and ANCA-associated GN |
|------------------------------------------------------------|
| AAV | ANCA-associated GN |
| Henoch–Schönlein purpura | Lupus nephritis |
| Cryoglobulinemic vasculitis | Anti-GBM disease |
| Drug-induced vasculitis | Other causes of rapidly progressive GN |
| Systemic infection | Thrombotic microangiopathies |
| Cholesterol embolization | Malignancies |
| Atrial myxoma with emboli | |

GBM, glomerular basement membrane; GN, glomerulonephritis.

(i) ANCA-negative patients might indeed have an auto-antibody capable of neutrophil activation just like their ANCA-positive counterparts, but current assays are not capable of detecting them [2].

(ii) ANCA negativity might be associated with the phase, extent and severity of disease. The following observations give credence to this point. ANCA negativity occurred more commonly in less severe disease such as localized GPA (i.e. disease limited to the upper or lower airways without other systemic involvements or constitutional symptoms) [6, 19, 20]. This is further supported by the observation that ANCA-negative patients tend to have a shorter prodromal period and fewer systemic upsets than their ANCA-positive counterparts [21]. In some patients who were ANCA-positive prior to treatment, ANCA was shown to disappear following immunosuppressive therapy with its disappearance.
being associated with an absence of disease activity [22].

(iii) ANCA negativity might be more characteristic of certain vasculitic syndromes (e.g. EGPA) and/or certain systemic involvements. Epidemiological data indicate that up to 55% of untreated EGPA patients are ANCA-negative [2]. Also in EGPA, there are differences in disease manifestation based on ANCA status; for instance, ANCA-positive patients were more likely to have necrotizing glomerulonephritis (75% of EGPA patients with glomerulonephritis are ANCA-positive) while ANCA-negative patients tend to develop cardiac and lung involvements [2, 23]. Based on these observations, we hypothesize that some EGPA patients who were ANCA-negative at diagnosis possibly undergo seroconversion to ANCA positivity at some point upon the development of glomerulonephritis or some other specific systemic involvement. This hypothesis however requires verification.

There is increasing evidence that ANCA plays a role in the pathogenesis of AAV [24], and this will be examined in the next section of this article. Besides ANCA, other antibodies found in the circulation of AAV patients have also been linked to the pathogenesis of AAV. For instance, studies in MPO-AAV patients have demonstrated the presence of serum anti-moesin autoantibodies that are thought to be involved in the secretion of inflammatory cytokines and chemokines and also in the pathogenesis of AAV [3, 25].

Also anti-plasminogen antibodies found in some AAV patients have been linked to increased susceptibility to venous thromboembolic events and greater severity of renal and systemic involvements in these patients [26, 27]. Another likely reason for the increased susceptibility to venous thromboembolic events in AAV may be due to the presence of hypercoagulability (as indicated by an elevated endogenous thrombin potential) and endothelial dysfunction/activation (as indicated by an increased level of factor VIII) found in AAV patients even in remission [28].

Studies have demonstrated the presence of antibodies against lysosome-associated membrane protein-2 (LAMP-2) in the circulation of patients with ANCA-associated glomerulonephritis [29–31]. It has been suggested that anti-LAMP-2 antibodies are a new ANCA subtype [29]. However, the prevalence and pathogenicity of these antibodies in AAV patients are still debatable [29–32]. Some authors have noted that anti-LAMP-2 antibodies are prevalent in AAV patients [29, 32] while other authors did not confirm such observations [31]. Recent reports suggest that the contrasting results obtained by these authors may perhaps be due to differences in the patient selection criteria and in the assays used [32]. In another recently published study involving ANCA-associated glomerulonephritis patients who were ANCA-negative, anti-LAMP-2 antibodies were shown to selectively bind native glomerular LAMP-2 instead of neutrophil LAMP-2, thereby suggesting a role in disease pathogenesis [18].

Pathogenesis of AAV

The exact pathogenesis of AAV is not fully known [33, 34], but in vivo studies in animal models, in vitro and clinical studies all point to the involvement of ANCA in the pathogenesis of AAV [35]. These findings are summarized in the following sections:

In vitro studies demonstrating the mechanism of ANCA-mediated vascular injury

In vitro studies have demonstrated that ANCA plays a role in the stimulation of cytokine-primed neutrophils, thereby inducing the degranulation of neutrophils, the release of oxygen free radicals and lytic enzymes which results in the lysis and disruption of endothelial cells [1, 2, 34, 36–38]. Similar events occurring in vivo would result in vasculitis via the same mechanism [1, 2]. Studies in rats and in AAV patients have shown that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, is capable of inhibiting ANCA-induced degranulation of neutrophils, thereby making it a potential therapeutic option for use in AAV patients [39].

In vivo studies in animal models demonstrating the pathogenicity of ANCA

In vivo studies in mice have also shown that MPO-ANCA is capable of inducing the development of pauci-immune vasculitis and glomerulonephritis [36, 37]. Injection of mouse anti-MPO immunoglobulin G (IgG) into immune-competent wild-type recipient mice or immune-deficient Rag2−/− mice produced pauci-immune necrotizing and crescentic glomerulonephritis in these mice [40–42]. The transfer of anti-MPO lymphocytes into immune-deficient mice has also resulted in necrotizing glomerulonephritis with glomerular immune deposits [40–42].

Clinical studies demonstrating the pathogenicity of ANCA

Transplacental transfer of maternal MPO-ANCA IgG is reported to have resulted in the development of glomerulonephritis and pulmonary haemorrhage in a neonate [43, 44].

Contribution of complement alternative pathway to the pathogenesis of AAV

Studies involving human subjects have shown that the activation of the complement alternative pathway plays a role in the pathogenesis of AAV [35, 36, 45–47] and that factors released by neutrophils after their stimulation by ANCA are believed to be involved in this complement alternative pathway activation [45]. The presence and level of factor B (Bb—a product of alternative complement pathway activation) in the plasma, glomeruli and urine of patients with active AAV have been linked to the severity of renal injury in these patients [46, 48].

Contribution of environmental factors to the development of ANCA and AAV

Studies have also shown the possible involvement of environmental factors such as drugs, air pollutants (e.g. silica) and infectious organisms like Staphylococcus aureus and Gram-negative bacteria in the development of ANCA and AAV [4, 35, 44, 49]. For instance, drugs such as propylthiouracil, hydralazine, cocaine-containing levamisole, minocycline, isoniazid and tumour necrosis factor-alpha inhibitors have been shown to induce AAV [4, 49–54]. In experimental studies, propylthiouracil-induced MPO-AAV and glomerulonephritis were linked to propylthiouracil-induced abnormalities in the structure and degradation of neutrophil extracellular traps (NETs) [55]. NETs induce cell death in neutrophils, and this process involves the release of chromatin fibres and intracytoplasmic proteins including PR3, MPO, lactoferrin, etc. [55].
In vivo studies in animal models have demonstrated the role of toll-like receptors (TLRs) in different aspects of disease pathogenesis (such as at level of tissue damage and also in the stimulation of autoimmune response) [56, 57]. TLRs are a class of receptors that are capable of recognizing microbial molecular patterns, thereby playing an important role in the innate immune system [58]. TLRs are increasingly expressed by leukocytes [58, 59]. TLR4 ligation has been shown to play a role in AAV induction and also in the stimulation of T helper 1 (Th17) and Th1 responses via TLR2 and TLR9 activation [56].

Contribution of genetic factors to the development of ANCA and AAV

Results from a large genome-wide association study involving Northern European GPA and MPA patients have confirmed the role of genetic factors in the pathogenesis of AAV [33]. This study demonstrated that,

(i) AAV had both major histocompatibility complex (MHC) and non-MHC associations;
(ii) GPA and MPA were genetically distinct disease entities;
(iii) HLA-DP, SERPINA 1 [the gene that encodes for α1-antitrypsin] and PRRT3 (the gene that encodes for PR3) were associated with PR3-ANCA in GPA with their specific loci and single-nucleotide polymorphism (SNP) being given as follows: HLA-DP (chromosome 6, SNP rs3117262), SERPINA 1 (chromosome 14, SNP rs7151526), PRRT3 (chromosome 19, SNP rs62132295);
(iv) HLA-DQ (on chromosome 6, SNP rs5000634) was associated with MPO-ANCA in MPA;
(v) Genetic associations were stronger for ANCA specificity than for specific AAV clinical syndromes.

Results from another study suggests that HLA-DRB1*15 alleles play a role in the pathogenesis of PR3-ANCA disease, especially among African Americans with an allele frequency of 94% [60].

Contributions of endogenous inflammatory mediators to the pathogenesis of AAV

One study has demonstrated the presence of endogenous antimicrobial peptide cathelicidin LL37 and interferon-alpha (IFN-α) in AAV patients, with their levels being more elevated in those with crescentic glomerulonephritis than in those without it, thereby suggesting the contribution of local and systemic inflammation to disease pathogenesis [61]. LL37 has also been shown to play a role in the pathogenesis of autoimmune disorders [61].

Role of B and T cells in the pathogenesis of AAV

B and T cells are believed to contribute to the pathogenesis of AAV. For instance, the existence in the normal immune system of a special subpopulation of B regulatory (Breg) cells that produce interleukin (IL)-10 and which may help regulate the action of the T-cell population [including T-regulatory (Treg) cells and T-helper (Th) 1 cells] has been demonstrated [62–64]. A study by Wilde et al. [64] has shown that there is a reduction in the number of Breg cells in both active and quiescent AAV. This study further went on to show that there was a positive correlation between Breg and Treg in quiescent AAV and suggests that Th1 cell suppression by Breg may be inadequate in active AAV [64]. Other studies in AAV patients have demonstrated the occurrence of impaired Treg cell functions coupled with the presence of effector T cells that are resistant to suppression by Treg cells [65]. Results from in vitro studies also indicate the possible role of a subpopulation of effector T cells called Th17 cells in the pathogenesis of AAV [34, 36, 56]. Also, studies in experimental animal (mice) with crescentic glomerulonephritis have demonstrated that Th17-mediated response and tissue injury is stimulated by microRNA-155 (miR-155) [66]. Also, an increased expression of miR-155 occurs in the kidneys of patients with ANCA-associated glomerulonephritis [66].

Clinical features of AAV

AAV is not a single disease entity but a group of multisystem disorders that share certain features in common. Therefore, the clinical features of AAV can be varied as they are dependent on disease stage, the specific organ system involvement(s), disease activity/severity and the chronicity/extent of damage to organ system involved [1, 67, 68]. Also, patients with GPA and EGPA have additional features that are characteristic of each of these vasculitic syndromes [1].

Patients often present with non-specific constitutional symptoms in addition to symptoms peculiar to the site of organ system involvement. Generalized non-specific symptoms may include a ‘flu-like illness’ present at disease onset, fever, malaise, weight loss, loss of appetite, myalgias, arthralgias and migratory arthropathy [1, 7]. Prodromal symptoms may be present for weeks to months in the absence of evidence of specific organ system involvement [69].

Renal involvement is one of the most clinically significant manifestations of AAV and perhaps the most severe. It occurs more frequently in MPA (90%) and in GPA (80%) and less frequently in EGPA (45%) [70]. Renal AAV that frequently manifests as RPGN can present with the following features: haematuria, proteinuria, active urinary sediments and renal failure [1, 7, 71]. RPGN in AAV can lead to end-stage renal disease (ESRD) within a very short period if not properly addressed. Renal involvement has been associated with increased morbidity and mortality in AAV [72]. In MPA and GPA, renal disease can also present as subacute or chronic nephritis [1]. With the exception of RLV whose manifestations are limited to the kidneys, the other AAV syndromes could be accompanied by manifestations involving other organ systems as presented below.

Pulmonary (lung) involvement is more frequent in GPA (90%) and EGPA (70%) and less frequent in MPA (50%) [70]. At least half of patients with ANCA-associated glomerulonephritis also have pulmonary disease [7]. Pulmonary involvement has also been associated with increased morbidity and mortality [72]. The extent of pulmonary involvement varies as it can range from transient infiltrates of the alveoli to severe pulmonary haemorrhage [7]. Severe pulmonary haemorrhage has been shown to be more predominant in PR3-ANCA disease, tightly correlated with renal AAV (the so-called pulmonary–renal syndrome) and associated with a higher incidence of long-term mortality despite treatment [73].

Upper airway involvement (disease of the ear, nose and throat) is more common in GPA (90%) and less common in MPA (35%) and EGPA (50%) [70]. It can manifest as sinusitis, rhinitis, subglottic stenosis or ocular inflammation (such as episcleritis, uveitis, iritis) [1, 7]. The presence of
upper airway involvement in AAV patients has been associated with an increased risk of relapse [74, 75]. Neurologic involvement occurs more frequently in EGPA (70%) and less frequently in GPA (50%) and MPA (30%) [70]. It usually manifests as peripheral neuropathy (mono-neuritis multiplex). Central nervous system involvement (most often in the form of granulomatosis meningeal inflammation) is less common [1, 7].

Cardiovascular involvement occurs less frequently in GPA or MPA and more frequently in EGPA (with a greater predominance in ANCA-negative EGPA patients than in their ANCA-positive counterparts) [1, 76]. Cardiovascular manifestations could include hypoplasia of the ventricles, temporary heart blocks, myocardial infarction, pericarditis, endocarditis or severe myocarditis [1]. Cardiovascular involvement has also been identified as a risk factor for relapsing AAV [77].

Gastrointestinal involvement has an equal frequency of occurrence (50% respectively) in the three main types of AAV. It can manifest as abdominal pain, haematochezia or perforation, all resulting from vasculitic ulceration of the small and large intestines [1, 7]. There could also be liver or pancreatic involvement [1].

Cutaneous involvement is very common and usually presents as purpura (especially in the lower extremities) [1, 7]. Other cutaneous lesions that could occur include nodules, petechiae, ecchymoses, ulcers, bullae, etc. [1, 7].

Renal biopsy as both a diagnostic and prognostic tool in renal AAV

Renal biopsy is the gold standard for the diagnosis of renal AAV [78]. This is especially true in light of the fact that not all patients with AAV are ANCA-positive. The classic histopathological features of ANCA-associated glomerulonephritis include the presence of segmental fibrinoid necrosis, glomerular crescents, and paucity or absence of glomerular immune deposits (pauci-immune glomerulonephritis) [1, 7]. However, some patients with ANCA-positive disease have been shown to demonstrate atypical pathology such as interstitial nephritis with vasa recta vasculitis in the absence of glomerulonephritis [79]. Such patients may eventually develop the classic lesions that characterize pauci-immune necrotizing glomerulonephritis [80].

Renal biopsy not only serves as a diagnostic tool in AAV but often has prognostic value [78]. For instance, Berden et al. developed an outcome-based classification system that divided renal pathology in ANCA-associated glomerulonephritis into four classes namely: focal, crescentic, mixed and sclerotic based on the proportion of normal, cellular crescentic and sclerotic glomeruli present [78]. The focal class was defined by the presence of ≥50% of normal glomeruli and was associated with a good renal outcome. The crescentic class consisted of ≥50% glomeruli with cellular crescents and was associated with the possibility for the recovery of renal function. The mixed class consisted of <50% normal, <50% crescentic and <50% globally sclerotic glomeruli and was associated with an intermediate risk for non-recovery of renal function. The sclerotic class consisted of ≥50% of globally sclerotic glomeruli and was associated with the poorest prognosis (a high probability of advancement to ESRD and death within a year of disease diagnosis) [78]. This classification system was found to have a predictive value for 1- and 5-year renal outcomes [78, 81]. In another study involving Chinese patients with renal AAV, this outcome-based classification system was also found to be useful to some degree in predicting renal response to treatment [82]. The limited predictability of the outcome-based classification system for response to therapy in this cohort of patients might have been associated with the type of induction treatment used in the study.

The role of imaging techniques in the localization of renal and other organ system involvements in AAV

Fluorodeoxyglucose-poston emission tomography/computed tomography (FDG-PET/CT) has been shown to be useful in localizing most organ system involvements in GPA (with the exception of the skin, eyes and nervous system) [83]. Fluorodeoxyglucose (18F-FDG or FDG), a radiolabeled glucose molecule, is the radiotracer used for this imaging technique. 18F-FDG has a radioactivity half-life of ~110 min identical to that of fluorine 18 ([18F]) and is not known to cause contrast-induced nephropathy [http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b15e3c-8484-433d-9f1c-c73a3c72861b] (date of access 09 January 2015). Further studies are needed to establish the use of this imaging technique in other types of AAV.

Assessment of disease activity and damage in AAV

Disease activity in AAV can be assessed using the BVAS now in its third version (BVAS v.3) [84, 85]. The BVAS is a checklist of pertinent signs, symptoms and features of active vasculitis and is useful both as a research tool and in aiding clinical decision-making [84]. BVAS v.3 represents an improvement on the two earlier versions and can be freely accessed online [http://vasculitis.org/images/documents/bvas%203.0.pdf] (date of access 19 March 2015); [http://www.epnetwork.co.uk/BVAS/bvas_flow.html](date of access 09 January 2015).

Damage in AAV can be assessed using the Vasculitis Damage Index (VDI) [55, 63, 86]. The VDI quantifies all damage (disease or treatment related) associated with vasculitis [63, 87]. The VDI is also a prognostic tool that is useful in predicting future relapses and mortality in AAV [87, 88]. However, due to concerns that VDI may not adequately indicate the full extent of damage experienced by patients with small- and medium-sized vessel vasculitis, a revised damage assessment tool called the Combined Damage Assessment Index (CDA) is presently being developed [89]. Unlike disease activity that is potentially reversible with the proper immunosuppressive treatment regimen, the damage is irreversible [63, 86].

Biomarkers of disease activity in AAV

At present there are no reliable biomarkers for monitoring disease activity in AAV. ANCA titre has been shown to correlate to some extent with disease activity, but to make therapeutic decisions based solely on ANCA titre is not encouraged. [1, 90, 91]. Research efforts are now focussed on identifying candidate serum proteins that could serve as biomarkers of disease assessments. There are ongoing
studies in different centres worldwide aimed at identifying potential serum biomarkers of disease activity in AAV. One such recently identified serum protein is B-cell activating factor belonging to the tumour necrosis family (BAFF). Serum levels of BAFF have been shown to be elevated in patients with MPO-AAV, with the levels being more elevated during active disease than in remission [92]. Furthermore, BAFF levels have been shown to correlate well with BVAS and erythrocyte sedimentary rate (ESR) levels [92]. In another recently published study involving patients from the RAVE (Rituximab in ANCA-Associated Vasculitis) trial with severe AAV, it was shown that the serum proteins, CXCL13 (BA-1), matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 were better at distinguishing active disease from remission than most other serum biomarkers including C-reactive protein and ESR [93]. Serum neutrophil gelatinase-associated lipocalin has also been shown to be useful in assessing disease activity in AAV [94]. As these are just research data, there is need for further validation studies of these biomarkers.

Conclusions

ANCA has been implicated in the pathogenesis of AAV. However, the absence of ANCA in the presence of clinicopathological evidences of disease (as seen in ANCA-negative patients) does suggest that other factors besides ANCA also play a role in the pathogenesis of AAV. Furthermore, several serum factors such as anti-moesin antibodies, IFN-α and cathelicidin LL37 have been put forward as possible contributors to disease pathogenesis. However, there is a need to fully establish and validate the roles played by these and other proposed contributory factors in the pathogenesis of AAV. Knowledge gained from such studies could prove useful in the development of target assays and specialized therapies that can further modify the diagnostic and therapeutic landscape of AAV.

Secondly, the present lack of validated diagnostic criteria for AAV does present some challenge. It is known that about a fifth of AAV patients present with an ANCA-negative status. This is further complicated by the fact that some patients will have relative and absolute contra-indications to a diagnostic renal biopsy, thereby making the final diagnosis of renal AAV all the more complex. This and other issues further underscore the need for the development of validated diagnostic criteria for AAV.

Thirdly, as there are no reliable biomarkers of disease activity in AAV at present, there is a need for concerted efforts aimed not only at identifying potential serum and urinary biomarkers but also at validating them for routine use in disease assessment.

Conflict of interest statement. None declared.

References

1. Jha V. Renal and systemic vasculitis. In: Floege J, Johnson RJ, Feehally J (eds). Comprehensive Clinical Nephrology. St. Louis, MO: Saunders, 2010, pp. 292–307
2. Homeister JW, Jennette JC, Falk RJ. Immunologic mechanisms of vasculitis. In: Alpern RJ, Moe OW, Caplan M (eds). Seldin and Giebisch’s The Kidney. Amsterdam: Elsevier, 2013, pp. 2817–2846
3. Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int 2013; 84: 244–249
4. Eisenberger U, Fakhouri F, Vanhille P et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005; 20: 1392–1399
5. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1–11
6. Ntatsaki E, Carruthers D, Chakravarty K et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 2014; 53: 2306–2309
7. Nachman PH, Denu-Ciocca CJ. Vasculitides. In: Lerma EV, Bern JS, Nissenson AR (eds). Current Diagnosis and Treatment: Nephropathy and Hypertension. New York: McGraw-Hill, 2008, pp. 265–275
8. Morán S, Little MA. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol 2014; 26: 37–41
9. Scott DG, Watts RA. Epidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol 2013; 17: 607–610
10. Herlyn K, Buckert F, Gross WL et al. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 2014; 53: 882–889
11. Bonaci-Nikolic B, Andrejevic S, Pavlovic M et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol 2010; 29: 893–904
12. Roth AJ, Ooi JD, Hess JG et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013; 123: 1773–1783
13. Lim LCL, Taylor JG, Schmitz JL et al. Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology: comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Am J Clin Pathol 1999; 111: 363–369
14. Savage J, Gillis D, Benson E et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111: 507–513
15. de Joode AA, Rozendaal C, van der Leij MJ et al. Performance of two strategies for urgent ANCA and anti-GBM analysis in vasculitis. Eur J Intern Med 2014; 25: 182–186
16. Noel N, André C, Bengoufa D et al. Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. Autoimmun Rev 2013; 12: 1118–1122
17. Falk RJ. In: Glassock RJ, Appel GB (eds). Clinical Spectrum of Antineutrophil Cytoplasmic Antibodies. Waltham, MA: UpToDate
18. Peschel A, Bosu N, Bentharkou A et al. Autoantibodies to hLAMP-2 in ANCA-negative pauci-immune focal necrotizing GN. J Am Soc Nephrol 2016; 25: 455–463
19. Finkelman JD, Lee AS, Hummel AM et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med 2007; 120: 643. e9–14
20. Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299–2309
21. Hedger N, Stevens J, Drey N et al. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant 2000; 15: 1593–1599
22. Geffriaud-Ricouard C, Noël LH, Chauveau D et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39: 125–136
23. Sinico RA, Bottero P. Churg–Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23: 355–366
24. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol 2008; 20: 55–60
25. Suzuki K, Nagao T, Itabashi M et al. A novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitis. Nephrol Dial Transplant 2013; 29: 1168–1177

26. Berden AE, Nolan SL, Morris HL et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol 2010; 21: 2169–2179

27. Hao J, Wang C, Gou SJ et al. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology (Oxford) 2014; 53: 300–306

28. Hilhorst M, Winckers K, Wilde B et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013; 40: 2042–2046

29. Kain R, Exner M, Brandes R et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088–1096

30. Kain R, Tadema H, Mckinney EF et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012; 23: 556–566

31. Roth AJ, Brown MC, Smith RN et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012; 23: 542–555

32. Kain R, Rees AJ. What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? Curr Opin Rheumatol 2013; 25: 26–34

33. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214–223

34. Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011; 70: 59–63

35. Jennette JC, Falk RJ, Gassim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 2011; 20: 263–270

36. Kallenberg CG. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 2011; 41: 224–231

37. Chen M, Kallenberg CG. New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009; 27: 108–114

38. Falk RJ, Terrell RS, Charles LA et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115–4119

39. Al-Ani B. Simvastatin inhibits neutrophil degranulation induced by antineutrophil cytoplasmic autoantibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Saudi Med J 2013; 34: 477–483

40. Jennette JC, Xiao H, Falk R et al. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol 2011; 169: 211–220

41. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955–963

42. Xiao H, Heeringa P, Liu Z et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167: 39–45

43. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398–401

44. Schlieben DJ, Korbet SM, Kimura RE et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCA. Am J Kidney Dis 2005; 45: 758–761

45. Xiao H, Schreiber A, Heeringa P et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52–64

46. Gou SJ, Yuan J, Chen M et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013; 83: 129–137

47. Xing GQ, Chen M, Liu G et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282–291

48. Gou SJ, Yuan J, Wang C et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013; 8: 1884–1891

49. Csernok E, Lamprecht P, Gross WL. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol 2010; 22: 43–48

50. Choi HK, Merkel PA, Walker AM et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis. Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405–413

51. Tan CD, Smith A, Rodriguez ER. Systemic necrotizing vasculitis induced by isoniazid. Cardiovasc Pathol 2012; 24: 181–182

52. Rendlergraf WF 3rd, Niles JS. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014; 26: 42–49

53. Silva SV, Ferreirra JP, Carvalho S et al. Antineutrophil cytoplasmic antibody positive systemic vasculitis in a patient treated with propylthiouracil. Acta Reumatol Port 2013; 38: 302–305

54. Reibltat T, Reibltat O. Appearance of ANCA-associated vasculitis under tumor necrosis factor-alpha inhibitors treatment. Am J Case Rep 2013; 14: 80–82

55. Nakazawa D, Tomaru U, Suzuki A et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3779–3787

56. van Timmeren MM, Heeringa P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 2012; 24: 8–14

57. Coughlan AM, Freeley SJ, Robson MG. Animal models of antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Immunol 2012; 169: 229–237

58. Tadema H, Abdolrahad WH, Stegeman CA et al. Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS ONE 2011; 6: e24315

59. Holle JL, Windmüller M, Lange C et al. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. Rheumatology (Oxford) 2013; 52: 1183–1189

60. Cao Y, Schmitz JL, Yang J et al. DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 2011; 22: 1161–1167

61. Zhang Y, Shi W, Tang S et al. The influence of cathelicidin LL37 in human antineutrophils cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 2013; 15: R161

62. Kolampokis I, Yoshizaki A, Tedder TF. IL-10 in the pathogenesis of ANCA-associated vasculitis under tumor necrosis factor-alpha inhibitors treatment. Arthritis Res Ther 2013; 15: S1

63. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL-10-deficient B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530–541

64. Wilde B, Thewissen M, Dannoiseux J et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013; 72: 1416–1419

65. Free ME, Bunch DO, McGregor JA et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a...
suppression-resistant effector cell population. *Arthritis Rheum* 2013; 65: 1922–1933

66. Krebs CF, Kopffer S, Paust HJ et al. MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN. *J Am Soc Nephrol* 2013; 24: 1955–1965

67. Schönemermark U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. *Nat Rev Nephrol* 2014; 10: 25–36

68. Robson J, Doli H, Suppiah R et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. *Ann Rheum Dis* 2013; 74: 177–184

69. Falk RJ, King ET, Stone RJ. In: Glassock RJ, Appel GB (eds). *Clinical Manifestations and Diagnosis of Granulomatosis with Polyangiitis (Wegener’s) and Microscopic Polyangiitis*. Waltham, MA: UpToDate

70. Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997; 337: 1512–1523

71. Tang W, Bose B, McDonald SP et al. The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. *Clin J Am Soc Nephrol* 2013; 8: 773–780

72. Little MA, Pusey CD. Glomerulonephritis due to antineutrophil cytoplasm antibody–associated vasculitis: an update on approaches to management. *Nephrology* 2005; 10: 368–376

73. Hruskova Z, Casian AL, Konopasek P et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. *Scand J Rheumatol* 2013; 42: 211–214

74. Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in ANCA small vessel vasculitis. *Ann Intern Med* 2005; 143: 621–631

75. Pagnoux C, Makrantas MA et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. *N Engl J Med* 2008; 359: 2790–2803

76. Comarmond C, Pagnoux C, Khelfa M et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. *Arthritis Rheum* 2013; 65: 270–281

77. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis. *Arthritis Rheum* 2012; 64: 542–548

78. Berden AE, Ferrario F, Hogen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2010; 21: 1628–1636

79. Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. *Am J Kidney Dis* 1994; 24: 130–141

80. Wen YK, Chen ML. Transformation from tubulointerstitial nephritis to crescentic glomerulonephritis: an unusual presentation of ANCA-associated renal vasculitis. *Ren Fail* 2006; 28: 189–191

81. Quintana LF, Pérez NS, De Sousa E et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. *Nephrol Dial Transplant* 2014; 29: 1764–1769

82. Chang DY, Wu LH, Liu G et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. *Nephrol Dial Transplant* 2012; 27: 2343–2349

83. Soussan M, Abisor N, Abad S et al. FDG-PET/CT in patients with ANCA-associated vasculitis: case series and literature review. *Autoimmun Rev* 2014; 13: 125–131

84. Suppiah R, Mukhtyar C, Flossmann O et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. *Rheumatology (Oxford)* 2011; 50: 899–905

85. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). *Ann Rheum Dis* 2009; 68: 1827–1832

86. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. *Arthritis Rheum* 1997; 40: 371–380

87. Seo P, Min YI, Holbrook JT et al. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis EtaNercept Trial (WGET). *Arthritis Rheum* 2005; 52: 2168–2178

88. Kamali S, Erer B, Artim-Esen B et al. Predictors of damage and survival in patients with Wegener’s granulomatosis: analysis of 50 patients. *J Rheumatol* 2010; 37: 374–378

89. Seo P, Luqmani RA, Flossmann O et al. The future of damage assessment in vasculitis. *J Rheumatol* 2007; 34: 1357–1371

90. Miloslavsky EM, Specks U, Merkel PA et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2013; 65: 2441–2449

91. Thai LH, Charles P, Resche-Rigon M et al. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. *Autoimmun Rev* 2014; 13: 313–318

92. Xin G, Chen M, Su Y et al. Serum B-cell activating factor is elevated with disease activity in patients with myeloperoxidase-antineutrophil cytoplasmic antibodies-associated vasculitis. *Arthritis Rheum* 2013; 64: 1358–1365

93. Monach PA, Warner RL, Tomasson G et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. *Ann Rheum Dis* 2013; 72: 1342–1350

94. Chen M, Wang F, Zhao MH. Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. *Rheumatology (Oxford)* 2009; 48: 355–358

*Received for publication: 16.8.14; Accepted in revised form: 5.3.15*